Burjeel Holdings PLC, listed on the Abu Dhabi Securities Exchange (ADX), reported a strong revenue increase to AED1.3 billion ($354 million) in Q3 2024, fueled by a surge in patient footfall and improved patient yield. Over the first nine months of 2024, total patient visits reached 4.8 million, as the company focused on expanding its network and enhancing specialty services.
Despite higher costs due to investments in oncology and regional expansion, Burjeel’s Q3 EBITDA grew by 5.1%, reaching AED273 million. The increased spending reflects the development of new facilities, along with elevated marketing efforts to attract international patients and promote regional growth.
CEO John Sunil highlighted Burjeel’s 14% revenue boost in Q3, noting a 12% rise in patient numbers and improved yield as outcomes of the company’s expanded super-specialty offerings. “Aligned with the UAE’s healthcare strategy, we will launch nine new primary care clinics, enhancing accessibility and strengthening our network through increased patient referrals,” Sunil said.
The Group remains focused on growth through investment in high-yield areas such as oncology, aiming to drive sustainable patient growth and long-term profitability.
